Piperazine, piperidine and tetrahydropyridine derivative of
indol-3-alkyl as 5-HT.sub.1D-.alpha. agonists
    1.
    发明授权
    Piperazine, piperidine and tetrahydropyridine derivative of indol-3-alkyl as 5-HT.sub.1D-.alpha. agonists 失效
    吲哚-3-烷基的哌嗪,哌啶和四氢吡啶衍生物作为5-HT1D-α激动剂

    公开(公告)号:US5807857A

    公开(公告)日:1998-09-15

    申请号:US737769

    申请日:1996-11-15

    摘要: Compounds of formula (I), or a salt or prodrug thereof, wherein Z represents an optionally substituted five-membered heteroaromatic ring selected from furan, thiophene, pyrrole, oxazole, thiazole, isoxazole, isothiazole, imidazole, pyrazole, oxadiazole, thiadiazole, triazole and tetrazole; E represents a chemical bond or a straight or branched alkylene chain containing from 1 to 4 carbon atoms; Q represents a straight or branched alkylene chain containing from 1 to 6 carbon atoms, optionally substituted in any position by a hydroxy group; T represents nitrogen or CH; U represents nitrogen or C--R.sup.2 ; V represents oxygen, sulphur or N--R.sup.3 ; --F--G-- represents --CH2--N--, --CH2--CH-- or --CH.dbd.C--; R.sup.1 represents C.sub.3-6 alkenyl, C.sub.3-6 alkynyl, aryl(C.sub.1-6)alkyl or heteroaryl(C.sub.1-6)alkyl, any of which groups may be optionally substituted; and R.sup.2 and R.sup.3 independently represent hydrogen or C.sub.1-6 alkyl are selective agonists of 5-HT1D receptors, being potent agonists of the human 5-HT1Dalpha receptor subtype, while possessing at least a 10-fold selective affinity for the 5-HT1Dalpha receptor subtype, relative to the 5-HT1Dbeta subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT1D receptors is indicated, while eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT1D receptor agonists.

    摘要翻译: PCT No.PCT / GB95 / 01129 Sec。 371日期1996年11月15日 102(e)日期1996年11月15日PCT提交1995年5月18日PCT公布。 公开号WO95 / 32196 (I)式(I)化合物或其盐或前药,其中Z表示选自呋喃,噻吩,吡咯,恶唑,噻唑,异恶唑的任选取代的五元杂芳环 ,异噻唑,咪唑,吡唑,恶二唑,噻二唑,三唑和四唑; E表示化学键或含有1至4个碳原子的直链或支链亚烷基链; Q表示任选被羟基取代的含有1至6个碳原子的直链或支链亚烷基链; T表示氮或CH; U表示氮或C-R2; V表示氧,硫或N-R3; -F-G-表示-CH 2 -N,-CH 2 -CH-或-CH = C-; R 1表示C 3-6烯基,C 3-6炔基,芳基(C 1-6)烷基或杂芳基(C 1-6)烷基,其中任何基团可以任选被取代; 并且R 2和R 3独立地表示氢或C 1-6烷基是5-HT1D受体的选择性激动剂,它是人5-HT1Dalpha受体亚型的有效激动剂,同时对5-HT1Dalpha受体亚型具有至少10倍的选择性亲和力, 相对于5-HT1Dbeta亚型; 因此,它们可用于治疗和/或预防临床症状,特别是偏头痛和相关疾病,其中指出5-HT1D受体的亚型选择性激动剂,同时引起较少的副作用,特别是不利的心血管事件,比 与非亚型选择性5-HT1D受体激动剂相关的那些。

    Substituted indolylpropyl-piperazine derivatives as 5-HT.sub.1D .alpha.
agonists
    4.
    发明授权
    Substituted indolylpropyl-piperazine derivatives as 5-HT.sub.1D .alpha. agonists 失效
    取代的吲哚基丙基哌嗪衍生物作为5-HT1Dα激动剂

    公开(公告)号:US5981529A

    公开(公告)日:1999-11-09

    申请号:US043440

    申请日:1998-03-18

    摘要: A class of 1-[3-(1H-indol-3-yl)propyl]-4-(2-phenylethyl)piperazine derivatives, substituted at the 5-position of the indole nucleus by a five-membered heteroaromatic moiety, on one or other of the ethylene carbon atoms of the phenethyl moiety by halogen, trifluoromethyl, alkyl, hydroxyalkyl or alkoxyalkyl, and optionally on the phenyl ring of the phenethyl moiety by halogen, trifluoromethyl, alkoxy or an oxazolidinone group and optionally by one or two further substituents, are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D .alpha. receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT.sub.1D .alpha. receptor subtype relative to the 5-HT.sub.1D .beta. subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT.sub.1D receptor agonists.

    摘要翻译: PCT No.PCT / GB96 / 02309 Sec。 371日期1998年3月18日 102(e)1998年3月18日PCT PCT 1996年9月19日PCT公布。 公开号WO97 / 11695 日期1997年4月3日一类1- [3-(1H-吲哚-3-基)丙基] -4-(2-苯基乙基)哌嗪衍生物,其在吲哚核的5-位被五元 三氟甲基,烷基,羟基烷基或烷氧基烷基,以及任选地在苯乙基部分的苯环上被卤素,三氟甲基,烷氧基或恶唑烷酮基团任选地在苯乙基部分的一个或另外的乙烯碳原子上, 一个或两个另外的取代基是5-HT1样受体的选择性激动剂,是人类5-HT1Dα受体亚型的有效激动剂,同时对5-HT1Dα受体亚型具有至少10倍的选择性亲和力 5-HT1D beta亚型; 因此,它们可用于治疗和/或预防临床状况,特别是偏头痛和相关疾病,其中指出5-HT1D受体的亚型选择性激动剂,同时引起较少的副作用,特别是不利的心血管事件,比 与非亚型选择性5-HT1D受体激动剂相关的那些。

    Substituted 1-indolylpropyl-4-phenethylpiperazadine derivatives
    7.
    发明授权
    Substituted 1-indolylpropyl-4-phenethylpiperazadine derivatives 失效
    取代的1-吲哚丙基-4-苯乙基哌嗪衍生物

    公开(公告)号:US5889008A

    公开(公告)日:1999-03-30

    申请号:US11308

    申请日:1998-02-05

    摘要: A class of 1-�3-(1H-indol-3-yl)propyl!-4-(2-phenylethyl) piperazine derivatives, substituted at the 5-position of the indole nucleus by a five-membered heteroaromatic moiety, and on the phenyl ring of the phenethyl moiety by fluoro, chloro, trifluoromethyl, alkoxy or an oxazolidinone group and optionally by one or two further substituents, are selective agonists of 5-HT.sub.1 -like receptors, being potent agonists of the human 5-HT.sub.1D .alpha. receptor subtype while possessing at least a 10-fold selective affinity for the 5-HT.sub.1D .alpha. receptor subtype relative to the 5-HT.sub.1D .alpha. subtype; they are therefore usefull in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT.sub.1D receptors is indicated, while eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT.sub.1D receptor agonists.

    摘要翻译: PCT No.PCT / GB96 / 01806 Sec。 371日期:1998年2月5日 102(e)1998年2月5日PCT PCT 1996年7月29日PCT公布。 公开号WO97 / 06159 日期1997年2月20日一类1- [3-(1H-吲哚-3-基)丙基] -4-(2-苯基乙基)哌嗪衍生物,其在吲哚核的5位被五元 氟代,氯代,三氟甲基,烷氧基或恶唑烷酮基以及任选地被一个或两个另外的取代基组成的苯乙基部分的苯环是5-HT1样受体的选择性激动剂,是人类的有效激动剂 5-HT1Dα受体亚型,同时相对于5-HT1Dα亚型对5-HT1Dα受体亚型具有至少10倍的选择性亲和力; 因此,它们可用于治疗和/或预防临床状况,特别是偏头痛和相关疾病,其中指出5-HT1D受体的亚型选择性激动剂,同时引起更少的副作用,特别是不利的心血管事件,比 与非亚型选择性5-HT1D受体激动剂相关的那些。

    6-Substituted-4-hydroxycinnolin-3-yl carboxylic acids and esters thereof
    9.
    发明授权
    6-Substituted-4-hydroxycinnolin-3-yl carboxylic acids and esters thereof 失效
    6-取代的4-羟基噌啉-3-基羧酸及其酯

    公开(公告)号:US4045439A

    公开(公告)日:1977-08-30

    申请号:US626531

    申请日:1975-10-28

    CPC分类号: C07D237/28

    摘要: 6-Substituted-4-hydroxycinnolin-3-yl carboxylic acids and esters thereof, processes for their preparation, and pharmaceutical compositions comprising any one of these compounds. A representative compound is ethyl 6-glycylamino-4-hydroxycinnolin-3-yl carboxylate hydrochloride. The compounds are active as inhibitors of effects following the combination of reagin-like antibodies and their antigens.

    摘要翻译: 6-取代的4-羟基噌啉-3-基羧酸及其酯,其制备方法和包含这些化合物中的任何一种的药物组合物。 代表性的化合物是6-甘氨酰氨基-4-羟基噌啉-3-基羧酸乙酯盐酸盐。 这些化合物作为抑制剂作为效应的抑制剂,与抗原样抗体及其抗原组合。